Artificial intelligence (AI) is a technology well suited for dealing with large amounts of information and has long been considered a promising tool in drug discovery. It has made steady in roads in the field in the last decade by improving the probability of success and bringing greater precision, speed, and cost-efficiency to a process notorious for high failure rates, very long timelines, and high cost. AI can deliver value in drug discovery in various ways including the identification of new therapeutic targets (biological molecules, typically proteins, associated with disease processes). It can help by discovering new indications for existing drugs, identifying new drug candidates, and designing new chemical compounds that could enable novel treatments. In this white paper, we focus on a specific application of AI in drug discovery, a process known as virtual screening.